Hedge fund manager targets Ampyra patent

Acorda Therapeutics Inc. (NASDAQ:ACOR) regained $0.83 to $36.89 on Wednesday after shedding 10% on Tuesday on news that an entity associated with hedge fund manager Kyle Bass filed an inter partes review with the U.S. Patent and Trademark Office challenging one of the company's patents for multiple sclerosis drug Ampyra dalfampridine.

The petitioner, Coalition for Affordable Drugs, challenged Patent No. 8,663,685, which expires in 2025 and covers methods to improve walking in MS patients by administering 10 mg of Ampyra -- a sustained-release formulation of 4-aminopyridine (4-AP) -- twice daily. ...